AZD3229 Tosylate

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Kit

Research Areas >> Cancer

KIT[1].

AZD3229 Tosylate is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines (GI50=1-50 nM). AZD3229 Tosylate demonstrates potent single digit nM growth inhibition across a broad cell panel, with good margin to KDR-driven effects. Selectivity over KDR can be rationalised predominantly by the interaction of water molecules with the protein and ligand in the active site and its kinome selectivity is similar to the best of the approved GIST agents[1].

[1]. Kettle JG, et al. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J Med Chem. 2018 Oct 11;61(19):8797-8810.

Pexidartinib | Masitinib (AB1010) | SU14813 | Dovitinib (TKI-258, CHIR-258) | Sitravatinib (MGCD516) | DCC-2618 | BLU-285 | Motesanib | OSI-930 | AST 487 | DCC-2618 | Telatinib | Amuvatinib (MP-470) | Flumatinib | AC 710